COPD exacerbations · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler probably leads to lower acute exacerbations of COPD (4‐week to 24‐week compared with placebo (moderate certainty).
1 finding from 1 review
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · Adults with COPD
1 finding from 1 review
FEV1 · Adults with COPD
1 finding from 1 review
Difference vs placebo in adjusted peak FEV1 (3‐week to 6‐month · Adults with COPD
1 finding from 1 review
Adverse events (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in adverse events (3‐week to 1‐year compared with placebo (high certainty).
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in exacerbations requiring steroids or antibiotics or both: number of… compared with aclidinium alone (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with formoterol (moderate certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in hospital admissions due to exacerbations: number of participants compared with formoterol (moderate certainty).
1 finding from 1 review
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to higher improvement in symptoms: number of participants with clinically… compared with formoterol (high certainty).
1 finding from 1 review
Lung function · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to lower adverse events (not including serious adverse events): number of… compared with formoterol (high certainty).
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in exacerbations requiring steroids or antibiotics or both: number of… compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to higher quality of life: number of participants with clinically significant… compared with placebo (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in hospital admissions due to exacerbations: number of participants compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to higher improvement in symptoms: number of participants with clinically… compared with placebo (high certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in quality of life: number of participants with clinically significant… compared with aclidinium alone (moderate certainty).
1 finding from 1 review
Lung function · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in adverse events (not including serious adverse events): number of… compared with placebo (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with aclidinium alone (moderate certainty).
1 finding from 1 review